$0.930
+0.035 (+3.81%)At close
GUTS Comparative Benchmarking
In the context of the broader market, GUTS competes directly with industry leaders such as BCDA and BIVI. With a market capitalization of $12.33M, it holds a significant position in the sector. When comparing efficiency, GUTS's gross margin of N/A stands against BCDA's N/A and BIVI's N/A. Such benchmarking helps identify whether Fractyl Health, Inc. is trading at a premium or discount relative to its financial performance.
Fractyl Health Inc Financial Performance
Fractyl Health has shown no revenue generation in the last several quarters, with total revenue reported at 3,000 USD in Q4 2024 and a net income loss of -24,970,000 USD in the same quarter. The gross margin is currently at 100% but is not sustainable due to lack of revenue in subsequent quarters.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.